Spironolactone–Furosemide Combination Therapy: Indications, Dosing, Monitoring, and Safety

Indications

Combination therapy (spironolactone 100 mg + furosemide 40 mg) is the preferred initial regimen for patients with moderate‑to‑severe cirrhotic ascites to achieve rapid natriuresis while preserving normokalemia. 1, 2, 3
For out‑patients with a first episode of minimal ascites, a single‑agent spironolactone (50–100 mg) may be started, but the majority will later require addition of furosemide. 1, 4
In a large cohort (n ≈ 3,860), initiating combination therapy from the outset was associated with superior outcomes compared with step‑wise escalation. 1, 3
In heart failure, low‑dose spironolactone (25–50 mg) is reserved for patients with persistent hypokalemia despite ACE‑inhibitor therapy or for those with severe disease; otherwise loop diuretics remain first‑line. 5

Begin with spironolactone 100 mg + furosemide 40 mg taken once daily in the morning. 1, 2, 6, 7
For a first‑episode ascites presentation, start spironolactone alone (50–100 mg) and add furosemide only if the response is inadequate. 6, 7

Increase both agents simultaneously every 3–5 days, preserving the 100 mg : 40 mg ratio, when weight loss or natriuresis is insufficient. 1, 2, 8
Maximum recommended doses are spironolactone 400 mg/day and furosemide 160 mg/day. 1, 2, 3, 6
Target weight loss is ≈ 0.5 kg/day in patients without peripheral edema; no strict limit is set when edema is present. 6, 7

Hypokalemia – temporarily hold furosemide (particularly in alcoholic hepatitis) to prevent further potassium loss. 1, 2, 8
Hyperkalemia – reduce or discontinue spironolactone; patients with parenchymal renal disease require lower spironolactone doses. 1, 2, 6
Hyponatremia (serum Na < 125 mmol/L) – reduce or stop diuretics and consider fluid restriction. 6, 9

Week 1: check serum potassium, creatinine, sodium, and BUN. 10
Weeks 2–4: repeat electrolyte panel every 5–7 days until values stabilize. 5, 10
Monitor blood pressure, body weight, and vital signs at each visit. 6, 7

Months 1–3: assess renal function and electrolytes at 1, 2, and 3 months. 5, 10
After 3 months: if stable, continue monitoring every 3–6 months. 5, 10

A 24‑hour urine sodium > 78 mmol/day (on an 88 mmol/day dietary sodium regimen) indicates adequate natriuresis. 6, 7
Spot urine Na/K > 1 correlates with sufficient sodium excretion; if ≤ 1, increase diuretic doses. 7

Discontinue or reduce diuretics when serum sodium falls below 120–125 mmol/L despite fluid restriction. 1, 4, 6
Stop spironolactone if serum potassium reaches ≥ 6.0 mmol/L. 5, 10
Halve spironolactone dose when potassium is 5.5–5.9 mmol/L. 10
Suspend or adjust therapy for acute kidney injury, hepatic encephalopathy, or a ≥ 50 % rise (or absolute value > 266 µmol/L) in serum creatinine. 6, 10

Use oral formulations exclusively for both agents in cirrhotic ascites. 1, 2, 3
Furosemide retains good oral bioavailability in cirrhosis; intravenous administration is associated with acute GFR reduction and azotemia. 1, 2, 11, 6
Single‑dose administration in the morning maximizes patient adherence. 1, 2

Replace spironolactone with amiloride (10–40 mg) if tender gynecomastia develops; amiloride has less anti‑androgen activity but is less potent as a diuretic. 1, 2, 4, 6

Avoid NSAIDs, which blunt natriuretic response and increase hyperkalemia risk. 5
Do not use thiazide diuretics when GFR < 30 mL/min unless combined synergistically with a loop diuretic. 5
Do not combine two renin‑angiotensin system blockers (ACE inhibitor + ARB). 12

All statements are supported by the cited references.